Atea制药公司报告说,一种新的丙型肝炎治疗非常有效,副作用微乎其微。 Atea Pharmaceuticals reports a highly effective new hepatitis C treatment with minimal side effects.

Atea制药公司已宣布其新的丙型肝炎治疗(结合Bemnifosbuvir和Ruzasvir)的第二阶段试验成功结果。 Atea Pharmaceuticals has announced successful Phase 2 trial results for their new hepatitis C treatment combining bemnifosbuvir and ruzasvir. 疗程在12周后治疗后达到98%的抗逆持续反应,没有严重的副作用或停止治疗。 The regimen achieved a 98% sustained virologic response at 12 weeks post-treatment, with no serious side effects or treatment discontinuations. 该公司计划于2025年初开始第3阶段试验,目的是提供更短、更方便的治疗,减少药丸数。 The company plans to begin Phase 3 trials in early 2025, aiming to offer a shorter, more convenient treatment with reduced pill count.